Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 8, 2026, 10:55 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1321–1344 of 3,978 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Pathophysiology Clear all

Conditions: Congestive Heart Failure
Interventions: Carvedilol; Drug
Lead sponsor: Shaddy, Robert, M.D.; Individual
Eligibility: 1 Day to 17 Years
Enrollment: 75 participants
Timeline: 2002 – 2006
U.S. locations: 17
States / cities: Los Angeles, California • Palo Alto, California • Denver, Colorado + 13 more

Conditions: Metabolic Dysfunction-assocated Steatohepatitis/ Nonalcoholic Fatty Liver Disease
Interventions: TVB-2640, Placebo; Drug · Other
Lead sponsor: Sagimet Biosciences Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 168 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2023
U.S. locations: 103
States / cities: Huntsville, Alabama • Madison, Alabama • Sun City, Arizona + 80 more

Conditions: Major Depressive Disorder
Interventions: HOLD: Videogame; Device
Lead sponsor: Akili Interactive Labs, Inc.; Industry
Eligibility: 25 Years to 55 Years
Enrollment: 84 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2018
U.S. locations: 4
States / cities: Garden Grove, California • North Miami, Florida • Charleston, North Carolina

Conditions: Executive Dysfunction
Interventions: Steep-tRAS, Flat-tRAS, Sham-tRAS; Device
Lead sponsor: Florida State University; Other
Eligibility: 18 Years to 35 Years
Enrollment: 30 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2027
U.S. locations: 1
States / cities: Tallahassee, Florida

Conditions: Dry Eye, Meibomian Gland Dysfunction (Disorder)
Interventions: Three 15-minute low-level light therapy sessions using Light Emitting Diodes of wavelength 633nm (Essilor epi-c plus).; Device
Lead sponsor: University of Houston; Other
Eligibility: 18 Years and older
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Parkinson's Disease
Interventions: Varenicline, Placebo; Drug
Lead sponsor: University of Michigan; Other
Eligibility: 45 Years and older
Enrollment: 34 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2019
U.S. locations: 1
States / cities: Ann Arbor, Michigan

Conditions: Thyroid Dysfunction
Interventions: Not listed
Lead sponsor: University of Arkansas; Other
Eligibility: 18 Years and older
Enrollment: 14 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2008
U.S. locations: 1
States / cities: Little Rock, Arkansas

Conditions: Anosognosia, Alzheimer's Disease, Mild Cognitive Impairment
Interventions: Not listed
Lead sponsor: University of Wisconsin, Madison; Other
Eligibility: 60 Years to 90 Years
Enrollment: 60 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2008 – 2011
U.S. locations: 1
States / cities: Madison, Wisconsin

Conditions: Sepsis, Septic Shock, Sepsis With Acute Organ Dysfunction
Interventions: Not listed
Lead sponsor: Axis Shield Diagnostics Ltd; Industry
Eligibility: 18 Years and older
Enrollment: 571 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2019
U.S. locations: 5
States / cities: Philadelphia, Pennsylvania • York, Pennsylvania • Nashville, Tennessee + 1 more

Conditions: SCID, Omenn's Syndrome, Reticular Dysgenesis, Wiskott-Aldrich Syndrome, Bare Lymphocyte Syndrome, Common Variable Immunodeficiency, Chronic Granulomatous Disease, CD40 Ligand Deficiency, Hyper IgM Syndrome, X-linked Lymphoproliferative Disease, Hemophagocytic Lymphohistiocytosis, Griscelli Syndrome, Chediak-Higashi Syndrome, Langerhan's Cell Histiocytosis
Interventions: Alemtuzumab 0.3 mg, Cyclophosphamide, Busulfan, Stem Cell Transplantation, Fludarabine phosphate 40 mg, Melphalan, Alemtuzumab 0.2 mg, Fludarabine phosphate 30 mg, MESNA; Drug · Biological
Lead sponsor: Masonic Cancer Center, University of Minnesota; Other
Eligibility: Up to 50 Years
Enrollment: 57 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2026
U.S. locations: 1
States / cities: Minneapolis, Minnesota

Conditions: Nonalcoholic Fatty Liver, Nonalcoholic Steatohepatitis, Obesity
Interventions: Phase II: Lifestyle treatment, Phase II: Control treatment, Phase I: Observational studies; Behavioral · Other
Lead sponsor: University of Missouri-Columbia; Other
Eligibility: 22 Years to 65 Years
Enrollment: 336 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2023
U.S. locations: 1
States / cities: Columbia, Missouri

Conditions: Parkinson Disease, Autonomic Dysfunction
Interventions: Exercise Stress Test; Other
Lead sponsor: University of Miami; Other
Eligibility: 50 Years to 85 Years
Enrollment: 30 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2018
U.S. locations: 1
States / cities: Coral Gables, Florida

Conditions: Pulmonary Hypertension, Diastolic Left Ventricular Dysfunction
Interventions: Ranolazine; Drug
Lead sponsor: Boston University; Other
Eligibility: 18 Years to 75 Years
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2014
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Breast Cancer, Cognitive Change, Cognitive Impairment, Quality of Life
Interventions: Sweep Seeker, Bird Safari, Jewel Diver, Master Gardener, Road Tour, Computerized Crossword Puzzles; Behavioral
Lead sponsor: Ohio State University; Other
Eligibility: 21 Years and older · Female only
Enrollment: 46 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2020
U.S. locations: 1
States / cities: Indianapolis, Indiana

Conditions: Metabolic Dysfunction-Associated Steatohepatitis (MASH)
Interventions: Resmetirom therapy, Comprehensive nutritional intervention, Standard dietary support; Drug · Behavioral
Lead sponsor: City University of New York; Other
Eligibility: 18 Years to 75 Years
Enrollment: 120 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 1
States / cities: New York, New York

Conditions: Cognitive Impairment, Mild, Dementia, Cardiovascular Diseases
Interventions: Atorvastatin 40 Mg Oral Tablet, Placebo oral tablet; Drug
Lead sponsor: Duke University; Other
Eligibility: 75 Years and older
Enrollment: 20,000 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2026
U.S. locations: 104
States / cities: Birmingham, Alabama • Tucson, Arizona • Little Rock, Arkansas + 70 more

Conditions: Mild Cognitive Impairment (MCI), Cognitive Training
Interventions: Cognitive Training; Other
Lead sponsor: Columbia University; Other
Eligibility: 55 Years to 89 Years
Enrollment: 240 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2030
U.S. locations: 4
States / cities: Miami, Florida • New York, New York • Durham, North Carolina + 1 more

Conditions: Mild Cognitive Impairment (MCI) Due to Alzheimer's Disease, Alzheimer's Disease
Interventions: Leronlimab (700mg); Drug
Lead sponsor: Weill Medical College of Cornell University; Other
Eligibility: 50 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: New York, New York

Conditions: Vulvodynia, Vulvar Vestibulitis, Dyspareunia, Pain
Interventions: Active Acupuncture, Placebo Acupuncture; Other
Lead sponsor: University of Illinois Chicago; Other
Eligibility: 18 Years to 45 Years · Female only
Enrollment: 6 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2022
U.S. locations: 1
States / cities: Wilmette, Illinois

Conditions: Microvascular Coronary Dysfunction
Interventions: Handgrip, Altitude simulation, Leg exercise; Other
Lead sponsor: Cedars-Sinai Medical Center; Other
Eligibility: 18 Years to 60 Years · Female only
Enrollment: 30 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014 – 2030
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Traumatic Brain Injury, Substance Use Disorder (SUD)
Interventions: TBI-RECOVER, Control; Behavioral
Lead sponsor: Ohio State University; Other
Eligibility: 18 Years and older
Enrollment: 900 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2030
U.S. locations: 1
States / cities: Columbus, Ohio

Conditions: Cyclic Vomiting Syndrome
Interventions: Ensure; Dietary Supplement
Lead sponsor: The Cleveland Clinic; Other
Eligibility: 18 Years and older
Enrollment: 24 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018
U.S. locations: 1
States / cities: Cleveland, Ohio

Conditions: Provoked Vestibulodynia
Interventions: Incobotulinum Toxin A, Placebo; Drug
Lead sponsor: Center for Vulvovaginal Disorders; Other
Eligibility: 18 Years and older · Female only
Enrollment: 54 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 2
States / cities: Washington D.C., District of Columbia • New York, New York

Conditions: Convergence Insufficiency, Traumatic Brain Injury, Concussion, Mild
Interventions: Virtual Eye Rotation Vision Exercise (VERVE), Sham VR Therapy; Device
Lead sponsor: New Jersey Institute of Technology; Other
Eligibility: 18 Years to 40 Years
Enrollment: 100 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2027
U.S. locations: 1
States / cities: Albuquerque, New Mexico

Search by objective public record fields.

Study to Evaluate the Safety of Twice Daily Oral Carvedilol

Study of TVB-2640 in Subjects With Nonalcoholic Steatohepatitis (NASH)

Software Treatments for Actively Reducing Severity of Cognitive Deficits in MDD (STARS-MDD)

Causal Role of the Aperiodic Signal for Working Memory

Low Level Light Therapy & Skin Pigmentation

Crossover Target Engagement Study of Cholinergic Mechanisms of Gait Dysfunction in Parkinson's Disease (Project #3 - Experiment 3 [UdallP3E3])

Thyroid Dysfunction in Head and Neck Surgery Patients

Functional Magnetic Resonance Imaging (fMRI) of Anosognosia in Amnestic Mild Cognitive Impairment (MCI) and Alzheimer's Disease (AD)

Assessment of Heparin Binding Protein for the Prediction of Severe Sepsis

Allogeneic Hematopoietic Stem Cell Transplant for Patients With Primary Immune Deficiencies

The Liver Health Study for Patients with NAFLD

Parkinson's Autonomic Responses to Treadmill Walking

Study of Ranolazine in the Treatment of Pulmonary Hypertension Associated With Diastolic Left Ventricular Dysfunction

Computerized Cognitive Training in Breast Cancer Survivors

Nutrition Intervention Combined With Resmetirom for MASH

Pragmatic Evaluation of Events And Benefits of Lipid-lowering in Older Adults

Cognitive Training and Neuroplasticity in Mild Cognitive Impairment: COGIT-2 Trial

Safety Assessment of Leronlimab and Its Effect on Brain Inflammation in Alzheimer's Disease

Acupuncture for Vulvodynia: A Pre-pilot Study

Development of a Novel Stress Testing Protocol to Define the Relationship Between Coronary Microvascular Dysfunction and Diastology in Women With Angina But No Evidence of Obstructive Coronary Artery Disease

Implementation of TBI-RECOVER in Substance Use Treatment

Applying Nutrient Drink Test in Understanding Pathophysiology of CVS

IncobotulinumtoxinA for Provoked Vestibulodynia With Overactive Pelvic Floor Muscle Dysfunction

Eye Recovery Automation for Post Injury Dysfunction (iRAPID)